Loading clinical trials...
Loading clinical trials...
To evaluate long-term safety and tolerability of carbetocin nasal spray (3.2 mg TID) in subjects with PWS
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
ACADIA Pharmaceuticals Inc.
NCT07197034 · Hyperphagia, Prader-Willi Syndrome, and more
NCT01968187 · Hyperphagia in Prader-Willi Syndrome
Children's of Alabama
Birmingham, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
University of California Irvine
Orange, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions